Suppr超能文献

遗传性癌症中意义不明的变异个体的临床管理:系统评价和荟萃分析。

Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis.

机构信息

Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Clinical Cancer Genetics and the Cancer Prevention and Control Platform, Moon Shots Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Clin Genet. 2021 Aug;100(2):119-131. doi: 10.1111/cge.13966. Epub 2021 Apr 21.

Abstract

Improper medical use of variant of uncertain significance (VUS) remains a concern in hereditary cancer genetic testing. The goal of this study was to assess the association between pathogenic and likely pathogenic (P/LP), VUS, and benign and likely benign (B/LB) genetic test results and cancer-related surgical and screening management. Systematic searches of Medline, Embase, EBSCO CINAHL Plus, and PsycINFO were conducted from 1946 to August 26, 2020. Eligible studies included individuals with cancer genetic test result and surgical or screening management outcomes. We reviewed 885 abstracts and 22 studies that reported relevant surgical and screening outcomes were included. Meta-analysis revealed significantly higher surgical rates among individuals with P/LP than among those with VUS for therapeutic mastectomy with contralateral prophylactic mastectomy (OR = 7.35, 95% CI, 4.14-13.64), prophylactic mastectomy (OR = 3.05, 95% CI, 1.5-6.19), and oophorectomy (OR = 6.46, 95% CI, 3.64-11.44). There were no significant differences in therapeutic mastectomy, or breast conservation or lumpectomy rates between individuals with P/LP and VUS, or in any outcomes between patients with VUS and B/LB. Studies evaluating screening outcomes were limited, and results were conflicting. Comprehensive analysis do not indicate that a significant number of individuals with VUS results undergo inappropriate clinical management.

摘要

变异意义不确定(VUS)的不当医学使用仍然是遗传性癌症基因检测中的一个关注点。本研究的目的是评估致病性和可能致病性(P/LP)、VUS 以及良性和可能良性(B/LB)基因检测结果与癌症相关的手术和筛查管理之间的关联。从 1946 年到 2020 年 8 月 26 日,对 Medline、Embase、EBSCO CINAHL Plus 和 PsycINFO 进行了系统检索。符合条件的研究包括具有癌症基因检测结果和手术或筛查管理结果的个体。我们审查了 885 份摘要和 22 项研究,其中有 22 项研究报告了相关的手术和筛查结果。荟萃分析显示,与 VUS 相比,P/LP 个体的手术率显著更高,包括保乳手术与对侧预防性乳房切除术(OR=7.35,95%CI,4.14-13.64)、预防性乳房切除术(OR=3.05,95%CI,1.5-6.19)和卵巢切除术(OR=6.46,95%CI,3.64-11.44)。P/LP 个体与 VUS 个体之间的保乳手术或乳房保留或肿瘤切除术率没有显著差异,或 VUS 个体与 B/LB 个体之间的任何结果均无显著差异。评估筛查结果的研究有限,结果存在冲突。综合分析表明,VUS 结果的个体中并没有相当数量的人接受不当的临床管理。

相似文献

8
Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.女性 BRCA1/2、PALB2、CHEK2 和 ATM 携带者的癌症风险管理。
Breast Cancer Res Treat. 2020 Jul;182(2):421-428. doi: 10.1007/s10549-020-05699-y. Epub 2020 May 22.

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验